Technical Data
Dopamine Receptor, D2L, D2S
The Dopamine D2 Receptor is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Two isoforms are reported for the D2 Dopamine Receptor, isoform 1 and isoform 2 which are expressed in the pituitary and brain; Isoform 1 is expressed seven times more than isoform 2 in the caudate nucleus.

Suitable for use in ELISA, Western Blot, Immunoprecipitation and Immunohistochemistry. Other applications have not been tested.

Recommended Dilutions:
ELISA: 0.5-1.0ug/ml
Western Blot: 1:1000. Detected Dopamine Receptor D2 on 10ug of human brain lysates.
Immunoprecipitation: 1-10ug/ml. Use 100-400ug of protein. An antibody made to this epitope has been shown to immunoprecipitate both the long and short forms.
Immunohistochemistry (Paraformaldehyde fixed sections): 2-10ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
Monkey brain tissue, rat or mouse brain lysate

Recommended Secondary Antibodies:
I1904-39: IgG, X-Adsorbed (HRP) Pab Gt x Rb
I1904-40A: IgG, H&L, X-Adsorbed (HRP) Pab Gt x Rb
I1904-46Q: IgG, H&L (HRP) Pab Gt x Rb

Storage and Stability:
May be stored at 4░C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20░C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
50ug-20░CBlue IceHumanRabbit
Synthetic peptide corresponding to the cytoplasmic loop #3 (28aa) of the human D2 receptor (NM_000795.2).
Purified by immunoaffinity chromotography.
Supplied as a liquid in PBS, pH 7.4, 0.1% BSA, 0.05% sodium azide.
Recognizes human Dopamine Receptor D2 short and long form at ~50kD. No significant homology with other dopamine receptors (D1 and D3-D5). Species Crosseactivity: monkey, mouse and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. EMBO 8: 4025 (1989). 2.áPNAS (1989) 86: 9762. 3.áNature 342: 926 (1990). 4.áNature 342: 923 (1989). 5.áMol. Pharmacol. 43: 666-676 (1993). 6.áBrain Res. 575: 309-314 (1992). 7.áJ. Neurochem. 57: 1363-1369 (1991). 8.áBBRC 184: 661-667 (1992). 9.áBrain Res. 578: 244-250 (1992). 10.áLife. Sci. 51: 1509-1516 (1992). 11. Gutierrez-Mecinas, M., et al., Eur. J. Neurol. 22: 1357-1367 (2005). 12. Lee, S.P., et al., J. Biol. Chem. 279: 35,671-35,678 (2004). 13. Lei, W., et al., J. Neurosci. 24: 8289-8299 (2004). 14. Macey, T.A., et al., Mol. Pharmacol. 66: 1635-1642 (2004). 15. Mengual, E., et al., Synapse 43: 151-162 (2002). 16. Wang, H., et al., J. Comparative Neurology 442: 392-404 (2002). 17. Neve, K.A., et al., Mol. Pharmacol. 60: 373-381 (2001).